Bioavailability of seocalcitol IV: Evaluation of lymphatic transport in conscious rats

Pharmaceutical Research

Volumn 23, Issue 11, 2006, Pages 2681-2688

  Grove, Mette ^a,b   Nielsen, Jeanet L ^a   Pedersen, Gitte P ^a   Müllertz, Anette ^b  

^a LEO PHARMA A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Long chain triglycerides; Lymphatic transport; Propylene glycol; Seocalcitol

Indexed keywords

LONG CHAIN TRIACYLGLYCEROL; PROPYLENE GLYCOL; SEOCALCITOL; TRITIUM;

ANIMAL EXPERIMENT; ARTICLE; CANNULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; DRUG TRANSPORT; INTESTINE LYMPH; LIPID SOLUBILITY; LYMPH FLOW; MALE; NONHUMAN; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CALCITRIOL; GASTROINTESTINAL TRACT; LYMPH; RATS; TRIGLYCERIDES;

EID: 33750620037     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9109-z     Document Type: Article

References (29)

1. C. J. Porter and W. N. Charman. Uptake of drugs into the intestinal lymphatics after oral administration. Adv. Drug Deliv. Rev. 25:71-89 (1997).
2. T. Gershanik and S. Benita. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur. J. Pharm. Biopharm. 50:179-188 (2000).
3. A. J. Humberstone and W. N. Charman. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv. Drug Deliv. Rev. 25:103-128 (1997).
4. C. M. O'Driscoll. Lipid-based formulations for intestinal lymphatic delivery. Eur. J. Pharm. Sci. 15:405-415 (2002).
5. M. M. Hussain. A proposed model for the assembly of chylomicrons. Atherosclerosis 148:1-15 (2000).
6. W. N. Charman and V. J. Stella. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int. J. Pharm. 34:175-178 (1986).
7. D. J. Hauss, S. C. Mehta, and G. W. Radebaugh. Targeted lymphatic transport and modified systemic distribution of CI-976, a lipophilic lipid-regulator drug, via a formulation approach. Int. J. Pharm. 108:85-93 (1994).
8. R. A. Myers and V. J. Stella. Systemic bioavailability of penclomedine (NSC-338720) from oil-in-water emulsions administered intraduodenally to rats. Int. J. Pharm. 78:217-226 (1992).
9. R. Holm and J. Hoest. Successful in silico predicting of intestinal lymphatic transfer. Int. J. Pharm. 272:189-193 (2004).
10. I. S. Mathiasen, K. W. Colston, and L. Binderup. EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. J. Steroid Biochem. Mol. Biol. 46:365-371 (1993).
11. A. Dahan and A. Hoffman. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur. J. Pharm. Sci. 24:381-388 (2005).
12. H. Liu, I. Adachi, I. Horikoshi, and M. Ueno. Mechanism of promotion of lymphatic drug absorption by milk fat globule membrane. Int. J. Pharm. 118:55-64 (1995).
13. M. Maislos, J. Silver, and M. Fainaru. Intestinal absorption of vitamin D sterols: differential absorption into lymph and portal blood in the rat. Gastroenterology 80:1528-1534 (1981).
14. J. L. Bollman, J. C. Cain, and J. H. Grindlay. Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat. J. Lab. Clin. Med. 33:1349-1352 (1948).
15. M. Grove, G. P. Pedersen, J. L. Nielsen, and A. Mullertz. Bioavailability of seocalcitol. I. Relating solubility in biorelevant media with oral bioavailability in rats - effect of medium and long chain triglycerides. J. Pharm. Sci. 94:1830-1838 (2005).
16. R. Holm, A. Mullertz, G. P. Pedersen, and H. G. Kristensen. Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids. Pharm. Res. 18:1299-1304 (2001).
17. G. Cruciani, M. Pastor, and W. Guba. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur. J. Pharm. Sci. 11(Suppl 2):S29-S39 (2000).
18. G. Cruciani, P. Crivori, P. A. Carrupt, and B. Testa. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J. Mol. Struct. Theochem 503:17-30 (2000).
19. T. Porsgaard and C. E. Hoy. Lymphatic transport in rats of several dietary fats differing in fatty acid profile and triacylglycerol structure. J. Nutr. 130:1619-1624 (2000).
20. C. J. Porter, S. A. Charman, A. J. Humberstone, and W. N. Charman. Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion. J. Pharm. Sci. 85:357-361 (1996).
21. S. M. Caliph, W. N. Charman, and C. J. Porter. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J. Pharm. Sci.89:1073-1084 1084(2000).
22. R. Holm, C. J. Porter, A. Mullertz, H. G. Kristensen, and W. N. Charman. Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats. Pharm. Res. 19:1354-1361 (2002).
23. R. Holm, A. Mullertz, E. Christensen, C. E. Hoy, and H. G. Kristensen. Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats. Eur. J. Pharm. Sci. 14:331-337 (2001).
24. Y. F. Shiau, D. A. Popper, M. Reed, C. Umstetter, D. Capuzzi, and G. M. Levine. Intestinal triglycerides are derived from both endogenous and exogenous sources. Am. J. Physiol. 248:G164-G169 (1985).
25. P. Tso, K. Ding, S. DeMichele, and Y. S. Huang. Intestinal absorption and lymphatic transport of a high gamma-linolenic acid canola oil in lymph fistula Sprague-Dawley rats. J. Nutr. 132:218-221 (2002).
26. P. B. Nielsen, A. Mullertz, T. Norling, and H. G. Kristensen. Comparison of the lymphatic transport of a lipophilic drug from vehicles containing alpha-tocopherol and/or triglycerides in rats. J. Pharm. Pharmacol. 53:1439-1445 (2001).
27. D. J. Hauss, S. E. Fogal, J. V. Ficorilli, C. A. Price, T. Roy, A. A. Jayaraj, and J. J. Keirns. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J. Pharm. Sci. 87:164-169 (1998).
28. S. M. Khoo, G. A. Edwards, C. J. Porter, and W. N. Charman. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J. Pharm. Sci. 90:1599-1607 (2001).
29. P. Gershkovich and A. Hoffman. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur. J. Pharm. Sci. 26:394-404 (2005).